Somerset-based Catalent on Thursday announced the appointment of Frederic Cedrone as vice president, corporate innovation.
Cedrone will collaborate closely with Catalent’s scientific teams and external partners to leverage innovative technologies in the development of emerging therapeutic modalities.
“Catalent has a proud history of building collaborative partnerships with innovators, academic institutions and industry specialists, and, through these, we have been able to bring many new technologies and drug modalities to a commercially-appropriate scale,” said Julien Meissonnier, chief scientific officer at Catalent. “I am delighted to welcome Frederic to Catalent, and his scientific and partnership-building experience will be valuable as we continue to assess new areas where the company can look to collaborate and invest further to drive the development of novel drugs and treatments of the future.”
Cedrone brings with him more than 25 years of experience in biologic drug development, including cell and gene therapies, and joins Catalent from Lysogene S.A. in Paris, where he held the role of vice president, alliances & business development.
Prior to Lysogene, Cedrone worked at Cellectis S.A., where he held a number of senior roles, both as a scientist and in business development, as well as partnering in the field of novel therapeutic modalities. He earned his doctorate degree in molecular biology and enzyme engineering from Marseille University in France, in addition to an engineer’s degree in biotechnology and a master’s degree in molecular genetics from Blaise Pascal University in Clermont-Ferrand, France.